Filtered By:
Education: Grants
Nutrition: Sodium

This page shows you your search results in order of date.

Order by Relevance | Date

Total 24 results found since Jan 2013.

Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Multinuclear MRI Reveals Early Efficacy of Stem Cell Therapy in Stroke
Transl Stroke Res. 2022 Jul 28. doi: 10.1007/s12975-022-01057-w. Online ahead of print.ABSTRACTCompromised adult human mesenchymal stem cells (hMSC) can impair cell therapy efficacy and further reverse ischemic recovery. However, in vitro assays require extended passage to characterize cells, limiting rapid assessment for therapeutic potency. Multinuclear magnetic resonance imaging and spectroscopy (MRI/S) provides near real-time feedback on disease progression and tissue recovery. Applied to ischemic stroke, 23Na MRI evaluates treatment efficacy within 24 h after middle cerebral artery occlusion, showing recovery of sodiu...
Source: Cell Research - July 28, 2022 Category: Cytology Authors: Shannon Helsper Xuegang Yuan F Andrew Bagdasarian Jacob Athey Yan Li Cesario V Borlongan Samuel C Grant Source Type: research

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

' Chipping away ' at the iceberg of health disparities
'Chipping away' at the iceberg of health disparities Kelly Palmer joined the Mel and Enid Zuckerman College of Public Health faculty in January, not long after earning her doctorate from the college. As a researcher studying diseases that disproportionately affect Black women, Palmer says her work is a team effort – and incredibly personal. Kyle Mittan Today University CommunicationsPalmer-web.jpg"Black women are my mother, my sister, my cousin, the members of my sorority, Alpha Kappa Alpha," said Kelly Palmer, an assistant professor in the University of Arizona Mel and Enid Zuckerman College of P...
Source: The University of Arizona: Health - February 14, 2022 Category: Universities & Medical Training Authors: mittank Source Type: research

Extended Ischemic Recovery After Implantation of Human Mesenchymal Stem Cell Aggregates Indicated by Sodium MRI at 21.1 T
Transl Stroke Res. 2022 Feb 7. doi: 10.1007/s12975-021-00976-4. Online ahead of print.ABSTRACTExtended therapeutic application remains a significant issue in the use of stem cell therapies to treat ischemic stroke. Along these lines, neurological recovery in a rodent model of ischemic stroke was evaluated following implantation of human mesenchymal stem cell aggregates (hMSC-agg), labeled with micron-sized particles of iron oxide, directly into the lateral ventricle contralateral to the ischemic lesion hemisphere. Longitudinally, disease progression and response to hMSC-agg therapy were assessed by 1H and 23Na magnetic res...
Source: Cell Research - February 8, 2022 Category: Cytology Authors: Shannon Helsper F Andrew Bagdasarian Xuegang Yuan Kaya Xu Jea-Young Lee Jens T Rosenberg Cesario V Borlongan Teng Ma Samuel C Grant Source Type: research

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Late-Breaking Data at ACC.21 Show XARELTO ® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization
RARITAN, N.J., May 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO® plus aspirin reduced first events by 15 percent among patients with PAD ...
Source: Johnson and Johnson - May 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
CONCLUSION: In diabetic patients at low cardiovascular risk, no treatment differs from placebo for vascular outcomes. In patients at increased cardiovascular risk receiving metformin-based background therapy, specific GLP-1 RAs and SGLT-2 inhibitors have a favorable effect on certain cardiovascular outcomes. PRIMARY FUNDING SOURCE: European Foundation for the Study of Diabetes, supported by an unrestricted educational grant from AstraZeneca. (PROSPERO: CRD42019122043). PMID: 32598218 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - June 29, 2020 Category: Internal Medicine Authors: Tsapas A, Avgerinos I, Karagiannis T, Malandris K, Manolopoulos A, Andreadis P, Liakos A, Matthews DR, Bekiari E Tags: Ann Intern Med Source Type: research

Aggregation of human mesenchymal stem cells enhances survival and efficacy in stroke treatment
In this study, we report the effects of short-term preconditioning of hMSCs via three-dimensional (3D) aggregation on stroke lesion recovery after intra-arterial (IA) transplantation of 3D aggregate-derived hMSCs (Agg-D hMSCs) in a transient middle cerebral artery occlusion (MCAO) stroke model. Compared with two-dimensional (2D) monolayer culture, Agg-D hMSCs exhibited increased resistance to ischemic stress, secretory function and therapeutic outcome. Short-term preconditioning via 3D aggregation reconfigured hMSC energy metabolism and altered redox cycle, which activated the PI3K/AKT pathway and enhanced resistance to in...
Source: Cytotherapy - September 17, 2019 Category: Cytology Source Type: research

Magnetic resonance electrical property mapping at 21.1 T: a study of conductivity and permittivity in phantoms, < i > ex vivo < /i > tissue and < i > in vivo < /i > ischemia.
This report investigates the feasibility and accuracy of EPT at 21.1 T for multiple RF coils and modes of operation using phantoms. Additionally, it demonstrates the EP of the &amp;lt;i&amp;gt;in vivo&amp;lt;/i&amp;gt; rat brain with and without ischemia. &amp;#13; &amp;#13; Helmholtz-based EPT was implemented in its Full-form, which demands the complex &amp;lt;i&amp;gt;B&amp;lt;sub&amp;gt;1&amp;lt;/sub&amp;gt;&amp;lt;sup&amp;gt;+&amp;lt;/sup&amp;gt;&amp;lt;/i&amp;gt; field, and a simplified form requiring either just the &amp;lt;i&amp;gt;B&...
Source: Physics in Medicine and Biology - July 14, 2019 Category: Physics Authors: Amouzandeh G, Mentink-Vigier F, Helsper S, Bagdasarian FA, Rosenberg JT, Grant S Tags: Phys Med Biol Source Type: research

Transcriptomic Analysis of Mecp2 Mutant Mice Reveals Differentially Expressed Genes and Altered Mechanisms in Both Blood and Brain
This study was carried out in accordance with the recommendations of National Animal Welfare Authority, Ireland. The protocol was approved by the Animal Ethical Committee Trinity College Dublin and HPRA.Author ContributionsAS performed the experiments and wrote the paper; KH provided assistance in the design and analysis of the RNAseq experiment; DT contributed to sample extraction and establishment of the colony; and DT and MG designed and supervised all the parts of the research and the writing of the manuscript.FundingThe study was funded by the Wellcome Trust Grant WT079408/C/06/Z issued to MG, and by an SFI FN Funded ...
Source: Frontiers in Psychiatry - April 29, 2019 Category: Psychiatry Source Type: research

Orally Administered Crocin Protects Against Cerebral Ischemia/Reperfusion Injury Through the Metabolic Transformation of Crocetin by Gut Microbiota
Conclusion Collectively, pharmacokinetic and pharmacodynamic association studies provide evidence that the gut microbiota plays a vital role in the fate of crocin and crocetin in the gastrointestinal tract. In addition, the cross-interaction between gut microbiota and crocin might mediate the activation of the cerebral-protective effect of orally administered crocin. Ethics Statement This study was carried out in accordance with the recommendations of ‘Institutional Animal Research Committee guidelines, Animal Ethics Committee of China Pharmaceutical University.’ The protocol was approved by the ‘An...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

Impaired Activity of Ryanodine Receptors Contributes to Calcium Mishandling in Cardiomyocytes of Metabolic Syndrome Rats
Conclusion Principal findings of this work are that abnormal Ca2+ transient amplitude, contractile dysfunction; and impaired relaxation of MetS cardiomyocytes underlies intrinsic dysfunctional RyR2 and SERCA pump. Abnormal activity of RyRs was evidenced by its decreased ability to bind [3H]-ryanodine. Although the MetS condition does not modify RyR2 protein expression, its phosphorylation at Ser2814 is decreased, which impairs its capacity for activation during ECC. The dysfunctional RyRs, together with a decreased activity of SERCA pump due to decreased Thr17-PLN phosphorylation suggest a downregulation of CaMKII in MetS...
Source: Frontiers in Physiology - April 29, 2019 Category: Physiology Source Type: research

Regulation of Tau Protein on the Antidepressant Effects of Ketamine in the Chronic Unpredictable Mild Stress Model
This study was carried out in accordance with the recommendations of the “Institutional Animal Care and Use Committee of China Medical University.” The protocol was approved by the “Institutional Animal Care and Use Committee of China Medical University.”Author ContributionsXWu and GW conceived and designed the experiments. YLi, RD, XR, WR, HYa, and YT performed the experiments. HYu, XZ, JY and XWa helped to analyze and interpret the data. GW drafted the manuscript. XWu, EX, YLu, and GZ provided critical revisions. All the authors reviewed and approved the final manuscript.FundingThe present stu...
Source: Frontiers in Psychiatry - April 29, 2019 Category: Psychiatry Source Type: research